Form 4: Delcath Systems Director Receives Equity Grant

Sentiment:

Statement of Changes in Beneficial Ownership


Director Elizabeth Czerepak was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Summary

  • Director Elizabeth Czerepak received a grant of 22,500 stock options on May 13, 2026.
  • The options have an exercise price of $11.61 per share.
  • The grant vests at a rate of 1/12th per month, beginning May 13, 2026, contingent on continued service as a director.
  • The options expire 10 years from the grant date or two years after the cessation of service for vested options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

  • Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

  • The grant results in potential future dilution for existing shareholders upon exercise.

Risks

  • Market price volatility may impact the value of the options.
  • Continued service requirement creates dependency on director retention.

Future Outlook

The options vest monthly over a one-year period, incentivizing the director's continued tenure through May 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board alignment with company performance and shareholder interests.

Comparison to Industry Standards

  • The use of a 12-month vesting schedule for director equity is consistent with standard practices for small-cap biotechnology firms.
  • The 10-year expiration term is standard for equity incentive plans.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity CompensationGrant of stock options under the 2020 Omnibus Equity Incentive Plan.05/13/2026Standard alignment of director compensation with company equity performance.

Stakeholder Impact

  • Shareholders: Potential minor dilution upon future exercise of options.
  • Director: Increased financial stake in the company's long-term performance.

Next Steps

  • Monthly vesting of options beginning May 13, 2026.

Key Dates

DateDescription
05/13/2026Date of option grant and commencement of vesting.
05/14/2026Date of filing.

Keywords

Delcath Systems, DCTH, Form 4, Insider Trading, Stock Options, Equity Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.